Piramal Pharma Limited has informed the Exchange regarding Cessation of Ms. Pratibha Mishra as Company Secretary & Compliance Officer of the company w.e.f. April 29, 2026.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma reported FY2026 consolidated revenue of Rs. 8,869 Cr but posted a net loss of Rs. 326 Cr (vs profit of Rs. 91 Cr in FY2025) due to Rs. 196 Cr in exceptional items including impairments and labour code transition costs. Standalone profit grew to Rs. 700 Cr from Rs. 691 Cr. The Board reappointed Ms. Nandini Piramal as Chairperson and Executive Director (effective April 2027), Mr. Peter DeYoung as Executive Director (effective October 2026), and two Independent Directors for second terms. Mr. Maneesh Sharma replaced Ms. Pratibha Mishra as Company Secretary and Compliance Officer effective April 29, 2026. The registered office will shift within Kurla, Mumbai from April 30, 2026.
The consolidated loss may concern investors, though standalone performance remained stable. Leadership continuity with the Piramal family (Nandini and Peter DeYoung) is maintained. The KMP transition in secretarial function is routine and not a governance red flag.